Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand - An open-label trial

被引:339
作者
Sfikakis, PP
Boletis, JN
Lionaki, S
Vigklis, V
Fragiadaki, KG
Iniotaki, A
Moutsopoulos, HM
机构
[1] Univ Athens, Sch Med, GR-11527 Athens, Greece
[2] Laikon Gen Hosp, Athens, Greece
[3] Gen Hosp, Athens, Greece
来源
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 02期
关键词
D O I
10.1002/art.20858
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Autoreactive B cells play a key role in tissue injury in systemic autoimmune disease, and therefore a treatment resulting in B cell depletion could have benefit. This open-label study was undertaken to evaluate the efficacy of the anti-CD20 monoclonal antibody rituximab in the treatment of lupus nephritis. Methods. Lupus patients with active proliferative nephritis (4 with focal disease and 6 with diffuse disease) received rituximab (4 weekly infusions of 375 mg/m(2)) combined with oral prednisolone. Clinical, laboratory, and immunologic responses, including peripheral lymphocyte subsets measured by flow cytometry, were prospectively assessed at monthly intervals for 12 months. Complete remission of nephritis was defined as normal serum creatinine and albumin levels, inactive urine sediment, and 24-hour urinary protein <500 mg. Partial remission was defined as >50% improvement in all renal parameters that were abnormal at baseline. Results. B cell depletion lasted from I month to 7 months and was well tolerated. Partial remission was achieved in 8 of 10 patients within a median of 2 months (range 1-4 months); in 5 of them, complete remission was subsequently established (at a median of 3 months from baseline), and it was sustained at 12 months in 4.As early as I month from baseline, the expression of the costimulatory molecule CD40 ligand on CD4+ T cells was decreased by 4-fold, and it was almost blocked when partial remission was clinically evident. The expression of T cell activation markers CD69 and HLA-DR was significantly decreased at time points when partial remission was observed, and was further decreased during complete remission. In contrast, in patients who did not exhibit a response or when relapse was detected in patients in whom an initial remission had been achieved, such decreases were not prominent. Serum concentrations of double-stranded DNA autoantibodies were decreased in all patients, regardless of clinical outcome. Conclusion. Following B cell depletion, clinical remission of lupus nephritis is associated with a decrease in T helper cell activation, suggesting an additional role for B cells, independent of autoantibody production, in promoting disease. A controlled trial to confirm these promising clinical results is warranted.
引用
收藏
页码:501 / 513
页数:13
相关论文
共 58 条
[1]   LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus -: Results from a randomized, double-blind, placebo-controlled study [J].
Alarcón-Segovia, D ;
Tumlin, JA ;
Furie, RA ;
McKay, JD ;
Cardiel, MH ;
Strand, V ;
Bagin, RG ;
Linnik, MD ;
Hepburn, B .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :442-454
[2]   The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].
Anolik, JH ;
Campbell, D ;
Felgar, RE ;
Young, F ;
Sanz, I ;
Rosenblatt, J ;
Looney, RJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459
[3]   LONG-TERM FOLLOW-UP OF PATIENTS WITH LUPUS NEPHRITIS - A STUDY BASED ON THE CLASSIFICATION OF THE WORLD-HEALTH-ORGANIZATION [J].
APPEL, GB ;
COHEN, DJ ;
PIRANI, CL ;
MELTZER, JI ;
ESTES, D .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (05) :877-885
[4]   Regulatory T cells under scrutiny [J].
Bach, JF .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (03) :189-198
[5]  
Balow JE, 1999, SYSTEMIC LUPUS ERYTH, P657
[6]   Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus [J].
Blanco, P ;
Palucka, AK ;
Gill, M ;
Pascual, V ;
Banchereau, J .
SCIENCE, 2001, 294 (5546) :1540-1543
[7]   Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis [J].
Boletis, JN ;
Ioannidis, JPA ;
Boki, KA ;
Moutsopoulos, HM .
LANCET, 1999, 354 (9178) :569-570
[8]   Rituximab in B-cell disorders other than non-Hodgkin's lymphoma [J].
Bosly, A ;
Keating, MJ ;
Stasi, R ;
Bradstock, K .
ANTI-CANCER DRUGS, 2002, 13 :S25-S33
[9]   RISK FOR SUSTAINED AMENORRHEA IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS RECEIVING INTERMITTENT PULSE CYCLOPHOSPHAMIDE THERAPY [J].
BOUMPAS, DT ;
AUSTIN, HA ;
VAUGHAN, EM ;
YARBORO, CH ;
KLIPPEL, JH ;
BALOW, JE .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (05) :366-369
[10]   A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis [J].
Boumpas, DT ;
Furie, R ;
Manzi, S ;
Illei, GG ;
Wallace, DJ ;
Balow, JE ;
Vaishnaw, A .
ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :719-727